Illumina, Inc. (NASDAQ:ILMN - Get Free Report) SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares of the company's stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Illumina Trading Up 4.0%
Shares of Illumina stock opened at $213.24 on Friday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $220.32. The stock's 50-day simple moving average is $186.84 and its 200 day simple moving average is $151.97. The stock has a market capitalization of $32.20 billion, a P/E ratio of 39.78, a P/E/G ratio of 2.89 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company's revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on ILMN shares. Sanford C. Bernstein reiterated a "market perform" rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. Leerink Partners increased their price objective on Illumina from $175.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, July 17th. Zacks Research upgraded Illumina from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 3rd. Deutsche Bank Aktiengesellschaft lowered Illumina to a "hold" rating in a report on Wednesday, August 5th. Finally, Barclays upped their price target on Illumina from $145.00 to $160.00 and gave the company an "underweight" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $188.40.
Get Our Latest Analysis on Illumina
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ILMN. Empowered Funds LLC lifted its holdings in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock worth $737,000 after acquiring an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC bought a new position in Illumina in the second quarter valued at $621,000. CW Advisors LLC bought a new position in Illumina in the second quarter valued at $275,000. Marshall Wace LLP boosted its holdings in shares of Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC boosted its holdings in shares of Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock worth $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.
About Illumina
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
